SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095821
Filing Date
2024-08-13
Accepted
2024-08-13 10:38:57
Documents
93
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mcrb-20240630.htm   iXBRL 10-Q 2864923
2 EX-10.5 mcrb-ex10_5.htm EX-10.5 75976
3 EX-31.1 mcrb-ex31_1.htm EX-31.1 12909
4 EX-31.2 mcrb-ex31_2.htm EX-31.2 12776
5 EX-32.1 mcrb-ex32_1.htm EX-32.1 7761
6 EX-32.2 mcrb-ex32_2.htm EX-32.2 7812
  Complete submission text file 0000950170-24-095821.txt   11215234

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20240630.xsd EX-101.SCH 1739810
96 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20240630_htm.xml XML 1724079
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37465 | Film No.: 241199380
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)